|
|
Insulet Corporation (NASDAQ: PODD) |
|
Overall company Market Share Q1 2025 |
*Market share is calculated based on total revenue.
News about Insulet Corporation Contracts |
November 1, 2024
As November unfolds, Insulet Corporation, a pioneer in tubeless insulin pump technology, is poised to make significant strides in enhancing diabetes management and raising awareness during National Diabetes Awareness Month and World Diabetes Day. The company is renowned for its innovative Omnipod brand of products, which are transforming the landscape of insulin delivery for individuals managing diabetes.Recognizing that diabetes management entails a myriad of daily decisions often stressful and overwhelming Insulet is taking proactive measures to support individuals navigating these complexities. Through a series of initiatives, the company aims to foster greater understanding and awareness of diabetes, ult...
|
August 8, 2024
Insulet Corporation, a leader in tubeless insulin pump technology, has shared its impressive financial and clinical performance for the second quarter of 2024, signaling its burgeoning influence in diabetes management. With a reported revenue of $488.5 million, representing a 23.2% increase year-over-year, the company has not only exceeded its guidance expectations but also solidified its position within the fast-evolving diabetes care market. Financial Growth: A Resounding Success The financial results underline a robust demand for Insulet s products, particularly the Omnipod insulin delivery systems, during a period when healthcare companies are navigating economic challenges. This revenue growth demonstra...
|
June 23, 2024
In a transformative stride for diabetes management, Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has presented unequivocally positive results from its pivotal Omnipod 5 Automated Insulin Delivery System (Omnipod 5) trial for type 2 diabetes. Amidst the grandeur of the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, Insulet showcased data that promises to elevate clinical outcomes and enhance the quality of life for individuals with type 2 diabetes. Concurrently, Insulet has launched the Omnipod 5 system in the United Kingdom and the Netherlands, marking a significant expansion in their mission to revolutionize diabetes care globa...
|
June 22, 2024
Insulets SECURE-T2D Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 DiabetesACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial. These results were shared at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. The landmark study assessed the impact of automated insulin delivery (AID) in a diverse group of people with type 2 diabetes, highlighting the promising outcomes and improved quality of life with the use o...
|
June 20, 2024
Insulet s Omnipod 5 with Expanded Sensor Integrations Now Available in the UK and the Netherlands: Revolutionizing Insulin Management for Diabetes PatientsACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the pioneer in tubeless insulin pump technology with its Omnipod brand, is thrilled to announce the full commercial launch of Omnipod 5 in the United Kingdom and the Netherlands. Omnipod 5, the next-generation insulin management system, is designed for individuals aged two years and older with type 1 diabetes. With its compatibility with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, this innovative device aims to transform the lives of diabetes patients in these...
|
February 7, 2024
Insulet s Omnipod 5 Receives CE Mark Approval for Integration with Abbott FreeStyle Libre 2 Plus Sensor: A Major Breakthrough for Type 1 Diabetes Management ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the renowned leader in tubeless insulin pump technology with its Omnipod brand, announced a significant development today. The Company has successfully obtained CE mark approval under the European Medical Device Regulation for the compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet s Omnipod 5 Automated Insulin Delivery System. This groundbreaking integration promises to revolutionize diabetes management for individuals aged two years and older with type 1 diabetes.The integration of t...
|
Publicly Traded Peers of Insulet Corporation
Dexcom Inc
Share Performance
-0.07%
Over The Past 5 Days
|
Dexcom Inc
Profile
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
More about Dexcom Inc 's Market Share
|
Embecta Corp
Share Performance
-19.97%
30 Days
|
Embecta Corp
Profile
Embecta Corp is a company that operates on a business-to-business (B2B) model, providing services or products to other businesses rather than individual consumers.
More about Embecta Corp 's Market Share
|
Medtronic Plc
Share Performance
+2.23%
Over The Past 5 Days
|
Medtronic Plc
Profile
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
More about Medtronic Plc's Market Share
|
Modular Medical Inc
Share Performance
-5.81%
Over The Past 5 Days
|
Modular Medical Inc
Profile
Modular Medical Inc operates with a business model focused on designing and manufacturing modular medical units, offering cost-effective and customizable solutions for healthcare providers looking to expand their facilities rapidly and efficiently. They aim to deliver innovative and turnkey solutions that can be easily deployed and scaled to meet the specific needs of their clients.
More about Modular Medical Inc's Market Share
|
Myomo Inc
Share Performance
-53.86%
This Year
|
Myomo Inc
Profile
Myomo Inc's business model revolves around the development and commercialization of advanced medical devices, specifically myoelectric orthotics for individuals with neuromuscular disorders.
More about Myomo Inc 's Market Share
|
Nemaura Medical Inc
Share Performance
-99.78%
One Year
|
Nemaura Medical Inc
Profile
Nemaura Medical Inc's business model revolves around developing innovative and cost-effective medical technologies and devices.
More about Nemaura Medical Inc 's Market Share
|
Semler Scientific inc
Share Performance
-40.22%
This Year
|
Semler Scientific inc
Profile
Semler Scientific Inc's business model revolves around providing medical diagnostic and testing devices, specifically focusing on vascular health.
More about Semler Scientific inc 's Market Share
|
Vivani Medical Inc
Share Performance
-29.88%
One Year
|
Vivani Medical Inc
Profile
Vivani Medical Inc is a medical device company that focuses on the development, manufacturing, and distribution of innovative healthcare products.
More about Vivani Medical Inc 's Market Share
|
Abbott Laboratories
Share Performance
+0.12%
30 Days
|
Abbott Laboratories
Profile
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
More about Abbott Laboratories's Market Share
|
Johnson and Johnson
Share Performance
-7.44%
This Quarter
|
Johnson and Johnson
Profile
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
More about Johnson and Johnson's Market Share
|
Tandem Diabetes Care Inc
Share Performance
-1.94%
Over The Past 5 Days
|
Tandem Diabetes Care Inc
Profile
Tandem Diabetes Care Inc is a medical device company that specializes in designing, manufacturing, and marketing insulin pumps. Their business model revolves around developing and selling technologically advanced insulin delivery systems to improve the quality of life for individuals with diabetes. By constantly innovating and focusing on customer needs, Tandem Diabetes Care Inc aims to capture a significant portion of the insulin pump market and establish itself as a trusted leader in the industry.
More about Tandem Diabetes Care Inc 's Market Share
|
Titan Pharmaceuticals Inc
Share Performance
+38.41%
This Quarter
|
Titan Pharmaceuticals Inc
Profile
Titan Pharmaceuticals Inc is a biopharmaceutical company that operates through a licensing business model. They focus on the development and commercialization of proprietary therapeutics for the treatment of different diseases and disorders. By licensing their products to strategic partners, they aim to leverage their technology and expertise for the commercial success of their pharmaceuticals.
More about Titan Pharmaceuticals Inc 's Market Share
|
Universal Biosensors Inc
Share Performance
0.00%
One Year
|
Universal Biosensors Inc
Profile
Universal Biosensors Inc has a business model focused on the development and commercialization of biosensor devices.
More about Universal Biosensors Inc 's Market Share
|
Sources: Insulet Corporation and all companies mentioned above in this report
|
